NASDAQ: KROSKeros Therapeutics Inc Stock
$10.65+0.24 (+2.31%)
Updated Jun 18, 2026
KROS Price
$10.65
Fair Value Price
N/A
Market Cap
$210.78M
52 Week Low
$9.69
52 Week High
$22.55
P/E
-4.21x
P/B
0.74x
P/S
6.53x
PEG
N/A
Dividend Yield
N/A
Revenue
$33.18M
Earnings
-$85.15M
Gross Margin
100%
Operating Margin
-272.15%
Profit Margin
-256.6%
Debt to Equity
0.09
Operating Cash Flow
-$57M
Beta
1.12
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
KROS Overview
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KROS's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KROS
Ranked#436 of 465
Ranked#436 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important KROS news, forecast changes, insider trades & much more!
KROS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KROS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KROS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KROS is good value based on its book value relative to its share price (0.74x), compared to the US Biotechnology industry average (4.95x)
P/B vs Industry Valuation
KROS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more KROS due diligence checks available for Premium users.
Valuation
KROS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.21x
Industry
15.77x
Market
9.47x
KROS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.74x
Industry
4.95x
KROS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KROS's financial health
Profit margin
Revenue
$367.0k
Net Income
-$23.7M
Profit Margin
-6,459.9%
KROS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KROS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$312.3M
Liabilities
$26.7M
Debt to equity
0.09
KROS's short-term assets ($290.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KROS's short-term assets ($290.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KROS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KROS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.5M
Investing
-$73.0k
Financing
-$2.3M
KROS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KROS vs Biotech Stocks
Keros Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.